Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  SI-BONE, Inc.    SIBN

SI-BONE, INC.

(SIBN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

SI-BONE to Present at the Morgan Stanley 18th Annual Global Healthcare Conference and the 2020 Cantor Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
09/01/2020 | 08:31am EDT

SANTA CLARA, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming Morgan Stanley 18th Annual Global Healthcare Conference and the 2020 Cantor Global Healthcare Conference.

For the Morgan Stanley Global Healthcare Conference, SI-BONE’s management is scheduled for a Fireside Chat on Tuesday, September 15, 2020 at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time.

For the Cantor Global Healthcare Conference, SI-BONE’s management is scheduled for a Fireside Chat on Wednesday, September 16, 2020 at 12:20 p.m. Eastern Time / 9:20 a.m. Pacific Time.

Interested parties may access a live and archived webcast of the events on the “Investors” section of the company’s website at: www.si-bone.com.

About SI-BONE

SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System. Studies have shown that the SI joint can be a source of pain in 15% to 30% of chronic low back pain. The iFuse Implant™, commercially available since 2009, is the only SI joint fusion device supported by multiple prospective clinical studies, including two RCTs, showing improved pain, patient function and quality of life resulting from treatment. There are over 80 peer-reviewed publications demonstrating the safety, durable effectiveness, and biomechanical and economic benefits unique to the iFuse Implant (www.si-bone.com/results). This body of evidence has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.

The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. The iFuse Implant System is also intended for sacroiliac fusion to augment stabilization and immobilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion. As well, the iFuse Implant System is intended for sacroiliac fusion in acute, non-acute, and non-traumatic fractures involving the sacroiliac joint. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit.

For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2020 SI-BONE, Inc. All Rights Reserved. 10825-09012020

Investor Contact:
Matt Bacso, CFA
investors@SI-BONE.com

Media Contact:
Joe Powers
jpowers@si-bone.com

Primary Logo

© GlobeNewswire 2020

share with twitter share with LinkedIn share with facebook
All news about SI-BONE, INC.
10/19SI BONE : To Report Third Quarter 2020 Financial Results on November 2, 2020
AQ
10/19SI-BONE To Report Third Quarter 2020 Financial Results on November 2, 2020
GL
10/16SI-BONE, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/15SI BONE : NASS virtual Conference Surgeon Panel Presentation
PU
10/14SI BONE : Announces Pricing of Public Offering of Common Stock
AQ
10/14SI-BONE Announces Pricing of Public Offering of Common Stock
GL
10/14SI BONE : Announces Launch of Public Offering of Common Stock
AQ
10/14SI-BONE Announces Launch of Public Offering of Common Stock
GL
10/08SI-BONE, INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
10/08SI BONE : Reports Preliminary Unaudited Revenue for the Third Quarter 2020 and P..
AQ
More news
Financials (USD)
Sales 2020 69,0 M - -
Net income 2020 -45,3 M - -
Net cash 2020 99,9 M - -
P/E ratio 2020 -13,8x
Yield 2020 -
Capitalization 706 M 706 M -
EV / Sales 2020 8,79x
EV / Sales 2021 6,66x
Nbr of Employees 262
Free-Float 96,4%
Chart SI-BONE, INC.
Duration : Period :
SI-BONE, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SI-BONE, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 27,50 $
Last Close Price 22,18 $
Spread / Highest target 35,3%
Spread / Average Target 24,0%
Spread / Lowest Target 12,7%
EPS Revisions
Managers
NameTitle
Jeffrey W. Dunn Chairman, President & Chief Executive Officer
Laura A. Francis Chief Operating & Financial Officer
Scott A. Yerby Chief Technology Officer
W. Carlton Reckling Chief Medical Officer & VP-Medical Affairs
Gregory K. Hinckley Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SI-BONE, INC.3.16%706
MASIMO CORPORATION54.86%13 450
NOVOCURE LIMITED46.87%12 512
ASAHI INTECC CO., LTD.-3.13%7 922
GETINGE AB2.10%5 516
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.53.79%4 665